Stoke Therapeutics Inc. reported revenue of $183.0 million for the nine months ended September 30, 2025, up from $13.9 million for the same period in 2024. The increase was primarily due to $150.8 million related to the IP license performance obligation, $11.5 million for global development activities under the Biogen Agreement, and $6.8 million related to the Acadia Agreement. Net income for the nine-month period was $51.0 million, or $0.85 per diluted share, compared to a net loss of $78.5 million, or $1.48 per share, in 2024. Research and development expenses rose to $96.2 million from $65.7 million, and sales, general and administrative expenses for the third quarter increased to $45.9 million from $36.0 million, driven by personnel and launch readiness expenses. As of September 30, 2025, the company held $328.6 million in cash, cash equivalents, and marketable securities, expected to fund operations through mid-2028. Patient recruitment for the Phase 3 EMPEROR study of zorevunersen is ongoing in the U.S., UK, and Japan, with enrollment expected to complete in the second half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104956965) on November 04, 2025, and is solely responsible for the information contained therein.
Comments